Metformin and oncogenic pathways: Crosstalk between energy sensing and tumor progression - PubMed
6 days ago
- #Metformin
- #AMPK/mTOR
- #Cancer Therapy
- Metformin, a diabetes drug, shows potential as an anti-cancer agent.
- It works through insulin-dependent and independent mechanisms, mainly via AMPK activation.
- AMPK activation disrupts the mTOR pathway, leading to reduced tumor growth.
- Metformin also affects oncogenic pathways like PI3K/Akt, Erk, and receptor tyrosine kinases.
- It alters tumor metabolism, angiogenesis, and immune responses.
- By inhibiting mitochondrial complex I, metformin impacts cancer cell energy production.
- Clinical results are mixed, indicating the need for more research.
- The review discusses metformin's potential and challenges in cancer therapy.